Mary R Welch1, Christian Grommes. 1. Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
Abstract
AIMS: Type 2 diabetes mellitus (DM2) affects 10% of the population, but little is known about how DM2 and antidiabetic medication impact glioblastoma (GBM) patients. PATIENTS & METHODS: We retrospectively reviewed GBM patients with DM2 seen at a single institution from 1998 to 2010. RESULTS: Of 988 GBMs, 124 (12.6%) were affected by DM2. Thirty-four developed DM2 after steroid use and 89 had pre-existing DM2. Median overall survival among diabetic GBMs was 10 months compared with 13 months among nondiabetics. Only 15% of diabetic patients achieved sustained steroid taper. Sixty-seven (54%) were managed with a single antidiabetic medication and, within this monotherapy group, Karnofsky Performance Score, resection status, steroid dependency and metformin use were the most important predictors of survival on multivariate analysis. CONCLUSION: The prevalence of DM2 among GBMs is similar to that of the general population. A more aggressive approach to steroid tapering and the choice of antidiabetic drug may improve survival within this patient population.
AIMS: Type 2 diabetes mellitus (DM2) affects 10% of the population, but little is known about how DM2 and antidiabetic medication impact glioblastoma (GBM) patients. PATIENTS & METHODS: We retrospectively reviewed GBM patients with DM2 seen at a single institution from 1998 to 2010. RESULTS: Of 988 GBMs, 124 (12.6%) were affected by DM2. Thirty-four developed DM2 after steroid use and 89 had pre-existing DM2. Median overall survival among diabetic GBMs was 10 months compared with 13 months among nondiabetics. Only 15% of diabeticpatients achieved sustained steroid taper. Sixty-seven (54%) were managed with a single antidiabetic medication and, within this monotherapy group, Karnofsky Performance Score, resection status, steroid dependency and metformin use were the most important predictors of survival on multivariate analysis. CONCLUSION: The prevalence of DM2 among GBMs is similar to that of the general population. A more aggressive approach to steroid tapering and the choice of antidiabetic drug may improve survival within this patient population.
Authors: Judith Schwartzbaum; Fredrik Jonsson; Anders Ahlbom; Susan Preston-Martin; Beatrice Malmer; Stefan Lönn; Karin Söderberg; Maria Feychting Journal: Cancer Epidemiol Biomarkers Prev Date: 2005-03 Impact factor: 4.254
Authors: Rachel L Derr; Xiaobu Ye; Melissa U Islas; Serena Desideri; Christopher D Saudek; Stuart A Grossman Journal: J Clin Oncol Date: 2009-01-12 Impact factor: 44.544
Authors: Sao Jiralerspong; Shana L Palla; Sharon H Giordano; Funda Meric-Bernstam; Cornelia Liedtke; Chad M Barnett; Limin Hsu; Mien-Chie Hung; Gabriel N Hortobagyi; Ana M Gonzalez-Angulo Journal: J Clin Oncol Date: 2009-06-01 Impact factor: 44.544
Authors: Kaisorn L Chaichana; Matthew J McGirt; Graeme F Woodworth; Ghazala Datoo; Rafael J Tamargo; John Weingart; Alessandro Olivi; Henry Brem; Alfredo Quinones-Hinojosa Journal: Neurol Res Date: 2009-07-08 Impact factor: 2.448
Authors: Craig J Currie; Chris D Poole; Sara Jenkins-Jones; Edwin A M Gale; Jeffrey A Johnson; Christopher Ll Morgan Journal: Diabetes Care Date: 2012-01-20 Impact factor: 19.112
Authors: Antje Wick; Tobias Kessler; Andrew E H Elia; Frank Winkler; Tracy T Batchelor; Michael Platten; Wolfgang Wick Journal: Neuro Oncol Date: 2018-01-22 Impact factor: 12.300
Authors: Laura Guarnaccia; Giovanni Marfia; Matteo Maria Masseroli; Stefania Elena Navone; Melissa Balsamo; Manuela Caroli; Silvia Valtorta; Rosa Maria Moresco; Rolando Campanella; Emanuele Garzia; Laura Riboni; Marco Locatelli Journal: Cancers (Basel) Date: 2021-12-27 Impact factor: 6.639
Authors: Laura Guarnaccia; Stefania E Navone; Matteo M Masseroli; Melissa Balsamo; Manuela Caroli; Silvia Valtorta; Rosa M Moresco; Rolando Campanella; Luigi Schisano; Giorgio Fiore; Valentina Galiano; Emanuele Garzia; Giuseppe C Appiani; Marco Locatelli; Laura Riboni; Giovanni Marfia Journal: Cancers (Basel) Date: 2022-03-10 Impact factor: 6.639